T Cell Receptor Engineered Lymphocytes for Cancer Therapy

Area of Science:

• Immunology
• Cancer Therapy
• Molecular Biology

Background:

• T lymphocytes play a crucial role in recognizing and eliminating target cells via T cell receptors (TCRs).
• Tumor-reactive TCRs can be engineered into T cells for adoptive cell therapy to treat advanced cancers.
• Current methods for isolating tumor-specific TCRs are complex, involving epitope identification, haplotype matching, and laborious T cell expansion.

Purpose of the Study:

• To present a streamlined protocol for generating, isolating, and engineering human T cells with tumor-reactive TCRs for adoptive cell therapy.
• To expand upon existing methodologies, leveraging single-cell sequencing advances.
• To facilitate the targeting of intracellular tumor antigens, expanding therapeutic options beyond chimeric antigen receptors (CARs).

Main Methods:

• Generation of human autologous dendritic cells from monocytes.
• In vitro priming and expansion of human antigen-specific T cells.
• Cloning of antigen-specific TCRs using single-cell VDJ sequencing.
• Validation of TCR expression and functionality.
• Rapid expansion of TCR-transduced T cells and T cell clones.

Main Results:

• The protocol synthesizes and expands upon existing methodologies for TCR isolation and T cell engineering.
• Advances in single-cell sequencing are integrated to streamline the process.
• The developed methodology enables the generation of T cells equipped with tumor-specific TCRs for therapeutic application.

Conclusions:

• This protocol provides a comprehensive approach to engineer T cells with tumor-reactive TCRs for adoptive cell therapy.
• The ability to target intracellular antigens significantly broadens the scope of TCR-based cancer therapies.
• This methodology offers a viable, albeit complex, strategy for developing targeted cancer immunotherapies.